When a woman takes medication during pregnancy, that drug doesn’t just stay in her bloodstream. Many medications can cross the placenta and reach the developing baby, potentially affecting growth, organ development, and long-term health. Understanding how drugs affect fetal development is essential for healthcare providers and expectant mothers to make informed decisions about medication use during this critical period.
Table of Contents
- How drugs cross the placental barrier
- The timing of drug exposure matters
- Before day 20 after fertilization
- During organogenesis (days 20 to 56)
- Second and third trimesters
- Congenital anomalies from drug exposure
- Intrauterine growth restriction
- Neonatal withdrawal syndromes
- Making informed decisions about medications
How drugs cross the placental barrier
The placenta serves as a connection between mother and baby, transferring oxygen and nutrients while removing waste products. However, it’s not a perfect barrier against medications. Drugs diffuse across the placenta similarly to how they cross other tissue barriers in the body, and several factors determine whether and how quickly a medication reaches the fetus.
Most drugs with a molecular weight below 500 daltons readily cross the placenta and enter fetal circulation. Smaller molecules pass through more easily than larger ones. Beyond size, other characteristics matter too. Medications that dissolve easily in fat (lipid-soluble drugs) cross more readily than water-soluble ones. Only the unbound portion of a drug in the bloodstream can cross the placenta, so drugs that bind heavily to proteins in maternal blood are less likely to reach the baby. Finally, drugs that aren’t ionized (electrically charged) move across the placental membrane more efficiently than ionized forms.
The maternal drug concentration is the major determinant of fetal drug exposure. Generally, it takes at least 30 to 60 minutes for equilibration between maternal blood and fetal tissues, though some drugs never reach similar concentrations on both sides of the placenta.
The timing of drug exposure matters
When a fetus is exposed to a potentially harmful drug can be just as important as what drug it is. Fetal development happens in stages, and each stage has different vulnerabilities.
Before day 20 after fertilization
Drugs given during this very early stage typically have an all-or-nothing effect-either causing the embryo to fail to develop, or having no effect at all. Birth defects are unlikely during this period because major organs haven’t started forming yet.
During organogenesis (days 20 to 56)
The first trimester, particularly the period of organogenesis, is the most susceptible time for significant malformations. This is when the baby’s major organs and body systems are forming. Drug exposure during this critical window can result in spontaneous abortion, structural birth defects, or permanent metabolic and functional problems that may not become apparent until later in life.
Second and third trimesters
After organogenesis, major structural birth defects become less likely. However, drugs can still alter the growth and function of normally formed organs and tissues. As the placenta’s ability to metabolize drugs increases, higher doses are typically needed to cause adverse effects.
Congenital anomalies from drug exposure
Certain medications have well-documented teratogenic effects-the ability to cause birth defects. These structural abnormalities can range from minor to severe and may affect any organ system.
Antiepileptic drugs are among those with the highest teratogenic potential. Valproate, for example, can cause neural tube defects (particularly spina bifida), cardiac anomalies, and developmental delays. Phenytoin exposure may result in fetal phenytoin syndrome, characterized by growth deficiency, distinctive facial features, and intellectual disability.
Warfarin, an anticoagulant, can cause fetal warfarin syndrome when taken during the first trimester, leading to nasal hypoplasia, bone abnormalities, and various degrees of intellectual disability. The risk is particularly high between weeks 6 and 9 of gestation.
Some antibiotics also pose risks. Tetracyclines can cause permanent yellowing of teeth, enamel hypoplasia, and slowed bone growth. Fluoroquinolones have been associated with cartilage damage in animal studies, though evidence in humans is less clear.
High doses of vitamin A and retinoid medications like isotretinoin carry severe teratogenic risks. Isotretinoin has a high teratogenic risk, causing multiple congenital malformations, spontaneous abortion, and intellectual disability, making it absolutely contraindicated during pregnancy.
Intrauterine growth restriction
Beyond causing structural defects, some drugs can impair fetal growth, leading to intrauterine growth restriction (IUGR). This condition means the baby is smaller than expected for its gestational age, typically weighing less than 90% of babies at the same stage of pregnancy.
Drugs and substances can contribute to IUGR by affecting placental function or directly impacting fetal development. Smoking cigarettes, drinking alcohol, and using recreational drugs during pregnancy are major risk factors. Certain medications associated with IUGR include steroids, warfarin, and phenytoin.
The growth restriction can be symmetric (the baby’s entire body is proportionally small) or asymmetric (the head is normal size but the body is small). IUGR affects about 10% of all pregnancies and requires careful monitoring with additional ultrasounds and prenatal appointments. Babies with IUGR face increased risks of complications at birth and may experience long-term health challenges.
Neonatal withdrawal syndromes
When a fetus is chronically exposed to certain drugs-particularly opioids, benzodiazepines, or antidepressants-the newborn may experience withdrawal symptoms after birth when the drug supply is suddenly cut off.
Neonatal opioid withdrawal syndrome (NOWS) occurs when babies receive opioid drugs through the placenta during pregnancy. The baby becomes dependent on these drugs in the womb, and when born, they experience withdrawal until the substance leaves their system.
Symptoms of NOWS typically begin within the first 72 hours after birth and can include excessive crying, tremors, irritability, feeding difficulties, sleep problems, fever, rapid breathing, and seizures in severe cases. According to estimates, one baby is diagnosed with neonatal abstinence syndrome every 24 minutes in the United States.
Treatment for NOWS depends on the severity of symptoms and may include supportive care such as frequent small feedings, swaddling, allowing the infant to room with the mother, and in more severe cases, medication like morphine or methadone. Some infants may need to stay in the hospital for several weeks while they recover.
Making informed decisions about medications
The overall rate of major structural birth defects in the United States is approximately 3%, and less than 1% of birth defects with known causes are due to medications. Most birth defects result from genetic, environmental, or unknown factors. However, this doesn’t mean medication use during pregnancy should be taken lightly.
Healthcare providers must carefully weigh the benefits of treating maternal conditions against potential risks to the developing fetus. Since 2015, the FDA has required that drug labels provide detailed information about pregnancy risks rather than simple letter categories, helping both providers and patients make more informed decisions.
Ideally, women should discuss medication use with their healthcare providers before becoming pregnant. This allows time to adjust treatment plans, switch to safer alternatives when possible, or ensure that the benefits of continuing necessary medications outweigh potential risks. Throughout pregnancy, open communication with healthcare providers about all medications-prescription, over-the-counter, and supplements-is essential for the health of both mother and baby.
What do you think? How can healthcare providers better educate women of reproductive age about medication safety before conception? Should there be more emphasis on preconception counseling for women with chronic conditions requiring ongoing medication?
References
- https://www.ncbi.nlm.nih.gov/books/NBK553086/
- https://www.merckmanuals.com/professional/gynecology-and-obstetrics/drug-safety-in-pregnancy/drug-safety-in-pregnancy
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2810038/
- https://my.clevelandclinic.org/health/diseases/24017-intrauterine-growth-restriction
- https://www.aafp.org/pubs/afp/issues/1998/1015/p1384.html
- https://my.clevelandclinic.org/health/diseases/23226-neonatal-abstinence-syndrome
- https://publications.aap.org/pediatrics/article/146/5/e2020029074/75310/Neonatal-Opioid-Withdrawal-Syndrome
- https://heal.nih.gov/research/infants-and-children/act-now
- https://www.cdc.gov/opioid-use-during-pregnancy/treatment/infants-opioid.html
- https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-final-rule
Leave a Reply